News Galapagos drops plan to split after 'market developments' Shortly after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Galapagos has had a change of heart.
News Bayer CEO warns of tough 2025 as turnaround plan beds in Things will get tougher before they get better at Bayer, according to CEO Bill Anderson, as the group reports its 2024 financial results.
News Medigene axes staff and refocuses its TCR pipeline Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline
News Novartis raises mid-term sales outlook on pipeline promise Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets
News 23andMe stock sell-off adds to its woes Shares in genetic testing company 23andMe continue to slide after prominent investors announce plans to sell their stakes
News 23andMe ends drug development and slashes staff 23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.
News Pushback rises against RFK Jr's new ACIP membership Medical groups have criticised Robert F Kennedy Jr's newly constituted CDC vaccine advisory panel, calling for the previous experts to be reinstated.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face